Aurobindo Pharma arm, Hilleman Labs Singapore ink pact for paediatric pentavalent vaccine

Published On 2023-09-28 07:00 GMT | Update On 2024-02-12 19:24 GMT

Telangana: Through a recent BSE filing, Aurobindo Pharma has informed that Auro Vaccines Private Limited, a wholly-owned subsidiary of the Company, has entered into a Licence Agreement with Hilleman Laboratories Singapore Pte. Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.

Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate.

"Please note that Auro Vaccines Private Limited is not a material subsidiary to the Company and the aforesaid entry into a Licence Agreement is not a material event. It may also be noted that at present entering into the aforesaid Licence Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials.

In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures," Aurobindo Pharma stated in a BSE filing.

Pentavalent vaccine provides protection to a child from 5 life-threatening diseases – Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib.

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over multiple therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Aurobindo Pharma arm, Hilleman Labs Singapore ink pact for paediatric pentavalent vaccine

Similar News

Keeping Medicines Without Licence Amounts to 'Offer for Sale', HC Upholds Chemist's Conviction

Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil

Zydus Foundation Vice Chairperson Meha Patel appointed as Member of CII National Committee on Art & Culture for 2025-26

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

Delhi to form special committee to crush fake medicine racket

Roche Pharma teams up with 10 Govt Hospitals to power up clinical trial capacities in India

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

Govt Allows Stickering, Orders New MRPs Post GST Reduction, AiMeD Welcomes Directive